Drug Trial Radar · NCT06764628
A Study of SHR-4375 in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Jan 9, 2025
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.
Conditions
- Solid Tumors
Interventions
SHR-4375Drug
SHR-4375 injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AEs)Time frame: From Day 1 to 90 days after last dose.
- Dose limiting toxicity (DLT)Time frame: From Day 1 to 12 months.
- Maximal tolerable dose (MTD)Time frame: From Day 1 to 12 months.
- Recommended phase 2 dose (RP2D)Time frame: From Day 1 to 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.